全文获取类型
收费全文 | 507篇 |
免费 | 38篇 |
国内免费 | 105篇 |
专业分类
儿科学 | 28篇 |
妇产科学 | 5篇 |
基础医学 | 42篇 |
口腔科学 | 32篇 |
临床医学 | 113篇 |
内科学 | 123篇 |
皮肤病学 | 7篇 |
神经病学 | 8篇 |
特种医学 | 69篇 |
外科学 | 27篇 |
综合类 | 38篇 |
预防医学 | 22篇 |
眼科学 | 11篇 |
药学 | 71篇 |
中国医学 | 1篇 |
肿瘤学 | 53篇 |
出版年
2021年 | 5篇 |
2020年 | 2篇 |
2019年 | 6篇 |
2018年 | 7篇 |
2017年 | 10篇 |
2016年 | 10篇 |
2015年 | 11篇 |
2014年 | 10篇 |
2013年 | 26篇 |
2012年 | 17篇 |
2011年 | 19篇 |
2010年 | 19篇 |
2009年 | 24篇 |
2008年 | 12篇 |
2007年 | 70篇 |
2006年 | 13篇 |
2005年 | 33篇 |
2004年 | 13篇 |
2003年 | 15篇 |
2002年 | 13篇 |
2001年 | 7篇 |
2000年 | 12篇 |
1999年 | 6篇 |
1998年 | 45篇 |
1997年 | 35篇 |
1996年 | 39篇 |
1995年 | 17篇 |
1994年 | 24篇 |
1993年 | 15篇 |
1992年 | 11篇 |
1991年 | 3篇 |
1990年 | 11篇 |
1989年 | 13篇 |
1988年 | 14篇 |
1987年 | 12篇 |
1986年 | 12篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1975年 | 3篇 |
1974年 | 1篇 |
1971年 | 1篇 |
1965年 | 1篇 |
1960年 | 1篇 |
排序方式: 共有650条查询结果,搜索用时 27 毫秒
71.
Weng X Liu L Barcellos LF Allison JE Herrinton LJ 《The American journal of gastroenterology》2007,102(7):1429-1435
BACKGROUND AND AIMS: Previous studies provide evidence that some immune-mediated diseases occur at greater frequency among inflammatory bowel disease (IBD) patients than in the general population. The present study examined the co-occurrence of IBD with common immune-mediated disorders including asthma, psoriasis, type 1 diabetes, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, vitiligo, autoimmune thyroiditis (Grave's and Hashimoto's), and chronic glomerulonephritis. METHODS: We conducted a cross-sectional study among members of the Kaiser Permanente Medical Care Program for the period 1996-2005. A total of 12,601 patients with at least two IBD diagnoses in computerized visit data were ascertained. Four persons without IBD were matched to each IBD patient on age, gender, and length of enrollment. Information on co-occurring diseases was obtained from computerized visit data for 1996-2005. Conditional logistic regression was used to estimate the odds ratio and 95% confidence interval for the association of IBD with immune-mediated disorders after adjusting for smoking. RESULTS: Seventeen percent of the IBD patients and 10% of the persons without IBD had a diagnosis for at least one immune-mediated disease. IBD patients were more likely to have asthma (1.5, 95% CI 1.4-1.6), psoriasis (1.7, 95% CI 1.5-2.0), rheumatoid arthritis (1.9, 95% CI 1.5-2.3), and multiple sclerosis (2.3, 95% CI 1.6-3.3). CONCLUSIONS: Among the immune-mediated diseases we studied, most were more common in IBD patients than in persons without IBD, suggesting that IBD shares common etiologic factors with other immune-mediated diseases. 相似文献
72.
Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency 总被引:4,自引:1,他引:4
Branten AJ; Reichert LJ; Koene RA; Wetzels JF 《QJM : monthly journal of the Association of Physicians》1998,91(5):359-366
We treated patients with idiopathic membranous nephropathy (iMGN) and renal
insufficiency, using: (i) (n = 15) monthly cycles of steroids (1 g
methyl-prednisolone i.v. on three consecutive days, followed by oral
prednisone 0.5 mg/kg/day months 1, 3 and 5) and chlorambucil (0.15
mg/kg/day months 2, 4 and 6); or (ii) (n = 17) oral cyclophosphamide
(1.5-2.0 mg/kg/day for 1 year) and steroids in a comparable dose. The
groups were comparable in age, renal function and levels of proteinuria.
During the 6 months preceding treatment, serum creatinine levels increased
from 148 +/- 50 to 219 +/- 73 mumol/l in the chlorambucil group and from
164 +/- 86 to 274 +/- 126 mumol/l in the cyclophosphamide group. Median
(range) follow-ups were: chlorambucil 38 months (8-71); cyclophosphamide 26
months (5-68) (NS). Renal function improved in both groups, but the
improvement was short-lived in the chlorambucil group; 12 months after
starting treatment, mean serum creatinine was 6.3 mumol/l lower in the
chlorambucil group and 121 mumol/l lower in the cyclophosphamide group (p
< 0.01). Four chlorambucil-treated patients developed ESRD, and five
needed a second course of therapy, whereas only one
cyclophosphamide-treated patient developed ESRD (p < 0.05). Remissions
of proteinuria occurred more frequently after cyclophosphamide treatment
(15/17 vs. 5/15; p < 0.01). Side-effects necessitated interruption of
treatment in six patients on cyclophosphamide and in 11 on chlorambucil (p
< 0.05). In our patients, oral cyclophosphamide was better tolerated
than oral chlorambucil. The suggested greater efficacy of the oral
cyclophosphamide regimen needs to be ascertained by longer follow-up.
相似文献
73.
Kevin Haynes Timothy Beukelman Jeffrey R. Curtis Craig Newcomb Lisa J. Herrinton David J. Graham Daniel H. Solomon Marie R. Griffin Lang Chen Liyan Liu Kenneth G. Saag James D. Lewis 《Arthritis \u0026amp; Rheumatology》2013,65(1):48-58
Objective
To compare the incidence of cancer following tumor necrosis factor α (TNFα) inhibitor therapy to that with commonly used alternative therapies across multiple immune‐mediated diseases.Methods
The Safety Assessment of Biological Therapeutics study used data from 4 sources: national Medicaid and Medicare databases, Tennessee Medicaid, pharmacy benefits plans for Medicare beneficiaries in New Jersey and Pennsylvania, and Kaiser Permanente Northern California. Propensity score–adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs) were computed to estimate the relative rates of cancer, comparing those treated with TNFα inhibitors to those treated with alternative disease‐modifying therapies. The cancer‐finding algorithm had a positive predictive value ranging from 31% for any leukemia to 89% for female breast cancer.Results
We included 29,555 patients with rheumatoid arthritis (RA) (13,102 person‐years), 6,357 patients with inflammatory bowel disease (1,508 person‐years), 1,298 patients with psoriasis (371 person‐years), and 2,498 patients with psoriatic arthritis (618 person‐years). The incidence of any solid cancer was not elevated in RA (HR 0.80 [95% CI 0.59–1.08]), inflammatory bowel disease (HR 1.42 [95% CI 0.47–4.26]), psoriasis (HR 0.58 [95% CI 0.10–3.31]), or psoriatic arthritis (HR 0.74 [95% CI 0.20–2.76]) during TNFα inhibitor therapy compared to disease‐specific alternative therapy. Among RA patients, the incidence of any of the 10 most common cancers in the US and of nonmelanoma skin cancer was not increased with TNFα inhibitor therapy compared to treatment with comparator drugs.Conclusion
Short‐term cancer risk was not elevated among patients treated with TNFα inhibitor therapy relative to commonly used therapies for immune‐ mediated chronic inflammatory diseases in this study.74.
Daniel H. Solomon Jeffrey R. Curtis Kenneth G. Saag Joyce Lii Lang Chen Leslie R. Harrold Lisa J. Herrinton David J. Graham Mary K. Kowal Bindee Kuriya Liyan Liu Marie R. Griffin James D. Lewis Jeremy A. Rassen 《The American journal of medicine》2013
Background
Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD).Methods
Subjects with rheumatoid arthritis participating in several different US insurance programs between 1998 and 2007 who received methotrexate were eligible. Those who added a TNF-α blocking agent were compared with subjects who added a nbDMARD in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage. We examined the composite cardiovascular end point of myocardial infarction, stroke, or coronary re-vascularization after 6 months.Results
We compared 8656 new users of a nbDMARD with 11,587 new users of a TNF-α blocking agent with similar baseline covariates. Incidence rates per 100 person-years for the composite cardiovascular end point were 3.05 (95% confidence interval [CI], 2.54-3.65) for nbDMARDs and 2.52 (95% CI, 2.12-2.98) for TNF-α blocking agents. The hazard ratio (HR) for the TNF-α blocking agent compared with nbDMARD carrying the first exposure forward was 0.80 (95%, CI 0.62-1.04), while the HR for the as-treated analysis was 0.71 (95% CI, 0.52-0.97). The potential cardiovascular benefit of TNF-α blocking agents was strongest among individuals ≥65 years of age (HR 0.52; 95% CI, 0.34 -0.77; P for interaction = 0.075).Conclusion
Among subjects with rheumatoid arthritis, TNF-α blocking agents may be associated with a reduced risk of cardiovascular events compared with an nbDMARD. Randomized controlled clinical trials should be considered to test this hypothesis. 相似文献75.
Chlorpropamide-induced pure white cell aplasia 总被引:2,自引:0,他引:2
We investigated the mechanism for isolated agranulocytosis and marrow pure white cell aplasia in an elderly man receiving 0.5 to 1.0 g per day of chlorpropamide (Chl) without other toxic drug exposure or overt systemic illness. Patient marrow revealed an absence of recognizable granulocytic precursors; megakaryocytes and erythroid precursors were normal. The WBC count was 1800/mm3 on admission with only 2% neutrophils; the absolute neutrophil count first exceeded 500/mm3 on the 17th day following cessation of Chl. A serum Chl level on admission was 100 micrograms/mL (acute phase, AP); no Chl was detected in serum (convalescent phase, CP) assessed on the 22nd hospital day. Antineutrophil antibodies were not detected, and T cell depletion failed to augment patient in vitro granulopoiesis. Patient AP serum produced potent complement-mediated inhibition (87% +/- 7%) of autologous granulocyte progenitors (CFU-GM) with minimal inhibition of erythroid (11% +/- 5%) or multipotent (5% +/- 4%) progenitor cells. Selective inhibition by patient AP serum of CFU-GM (74% +/- 11%) was also seen against two allogeneic marrows. Patient CP serum no longer inhibited (6% +/- 4%) autologous CFU-GM. Addition of Chl (5 to 120 micrograms/mL) to CP serum but not to control serum resulted in potent drug concentration-dependent complement-mediated inhibition of autologous and allogeneic CFU-GM. Inhibition of CFU-GM in the presence of Chl was no longer demonstrable following immunoabsorbent removal of IgG from patient serum. Patient serum in the presence of Chl had limited activity against morphologically recognizable marrow granulocytic precursors in a microimmunofluorescence assay. These results are most consistent with the development of Chl-dependent, selective antibody-mediated immune inhibition of granulopoiesis. 相似文献
76.
Jochim S Terhaar sive Droste Mike E Craanen Rene WM van der Hulst Joep F Bartelsman Dick P Bezemer Kim R Cappendijk Gerrit A Meijer Linde M Morsink Pleun Snel Hans ARE Tuynman Roy LJ van Wanrooy Eric IC Wesdorp Chris JJ Mulder 《World journal of gastroenterology : WJG》2009,15(9):1085-1092
AIM: To assess the prevalence and location of advanced neoplasia in patients undergoing colonoscopy, and to compare the yield per indication. METHODS: In a multicenter colonoscopy survey (n = 18 hospitals) in the Amsterdam area (Northern Holland), data of all colonoscopies performed during a three month period in 2005 were analyzed. The location and the histological features of all colonic neoplasia were recorded. The prevalence and the distribution of advanced colorectal neoplasia and differences in yield between indication clusters were evaluated. Advanced neoplasm was defined as adenoma 〉 10 mm in size, with 〉 25% villous features or with high-grade dysplasia or cancer. RESULTS: A total of 4623 eligible patients underwent a total colonoscopy. The prevalence of advanced neoplasia was 13%, with 281 (6%) adenocarcinomas and 342 (7%) advanced adenomas. Sixty-seven percent and 33% of advanced neoplasia were located in the distal and proximal colon, respectively. Of all patients with right-sided advanced neoplasia (n = 228), 51% had a normal distal colon, whereas 27% had a synchronous distal adenoma. Ten percent of all colonoscopies were performed in asymptomatic patients, 7% of whom had advanced neoplasia. In the respective procedure indication clusters, the prevalence of rightsided advanced neoplasia ranged from 11%-57%. CONCLUSION: One out of every 7-8 colonoscopies yielded an advanced colorectal neoplasm. Colonoscopy is warranted for the evaluation of both symptomatic and asymptomatic patients. 相似文献
77.
78.
79.
80.
Abruzzo LV; Schmidt K; Weiss LM; Jaffe ES; Medeiros LJ; Sander CA; Raffeld M 《Blood》1993,82(1):241-246
We describe a patient with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD), who subsequently developed large-cell immunoblastic lymphoma of B-cell immunophenotype. At the time of the initial diagnosis, histologic examination of an inguinal lymph node showed typical features of AILD, and there was no evidence of a monoclonal B-cell population by immunohistochemical analysis. In situ hybridization and Southern blot analysis for Epstein-Barr virus (EBV) were negative. At autopsy 2 years later, the patient had widespread lymph node and organ involvement by large-cell immunoblastic lymphoma of B-cell immunophenotype. Southern blot analysis performed on DNA extracted from lymph nodes, liver, and spleen showed two patterns of Ig heavy chain and kappa light chain gene rearrangements. The T-cell receptor beta chain gene was in the germline configuration. Analysis with an EBV terminal repeat region probe showed two clonal populations that paralleled the Ig gene rearrangement studies. Double-labeling immunohistochemistry and in situ hybridization confirmed the presence of EBV within the neoplastic B cells. The data support the hypothesis that EBV was not etiologically related to AILD in this case, and that EBV proliferation may occur after the onset of the disease. Further, the data suggest that some B-cell lymphomas that arise in the setting of AILD resemble EBV-associated B-cell lymphomas that arise in other immunodeficiency states. 相似文献